Literature DB >> 34128127

Use of Shockwave intravascular lithotripsy for the treatment of symptomatic and severely calcified superior mesenteric artery stenosis.

Oscar Balboa Arregui1, Carmen Seoane Pose2, María Balboa Alonso3, Teresa Bolaño Pampín2.   

Abstract

BACKGROUND: We present the use of intravascular lithotripsy as a treatment for highly calcified superior mesenteric artery stenosis. CASE
PRESENTATION: A 67-year-old diabetic man had chronic postprandial abdominal pain and weight loss. Computed tomography angiography revealed highly calcified stenosis of the superior mesenteric artery. Selective angiography confirmed severe stenosis. A Shockwave lithotripsy balloon catheter was successfully used via brachial access to modify calcified plaque and increase vascular lumen. After 12 months of follow-up the patient had gained weight and had no abdominal postprandial pain.
CONCLUSION: Intravascular lithotripsy could be considered a new treatment modality to modify calcified lesions in the visceral arteries. More controlled studies are needed to demonstrate the efficacy, safety and feasibility of this new technology. LEVEL OF EVIDENCE: 4, Case Report.

Entities:  

Keywords:  Chronic mesenteric ischemia; Intravascular lithotripsy; Superior mesenteric artery stenosis

Year:  2021        PMID: 34128127     DOI: 10.1186/s42155-021-00243-5

Source DB:  PubMed          Journal:  CVIR Endovasc        ISSN: 2520-8934


  9 in total

Review 1.  Open or percutaneous revascularization for chronic splanchnic syndrome.

Authors:  André S van Petersen; Jeroen J Kolkman; Roland J Beuk; Ad B Huisman; Cees J A Doelman; Robert H Geelkerken
Journal:  J Vasc Surg       Date:  2010-03-20       Impact factor: 4.268

2.  Chronic mesenteric ischemia: 20 year experience of open surgical treatment.

Authors:  A Lejay; Y Georg; E Tartaglia; O Creton; B Lucereau; F Thaveau; B Geny; N Chakfe
Journal:  Eur J Vasc Endovasc Surg       Date:  2015-02-26       Impact factor: 7.069

3.  Chronic mesenteric ischemia.

Authors:  Jayaprakash Sreenarasimhaiah
Journal:  Curr Treat Options Gastroenterol       Date:  2007-02

Review 4.  Celiac artery stenosis: an underappreciated and unpleasant surprise in patients undergoing pancreaticoduodenectomy.

Authors:  George H Sakorafas; Michael G Sarr; George Peros
Journal:  J Am Coll Surg       Date:  2007-10-18       Impact factor: 6.113

5.  Feasibility of Shockwave Coronary Intravascular Lithotripsy for the Treatment of Calcified Coronary Stenoses.

Authors:  Todd J Brinton; Ziad A Ali; Jonathan M Hill; Ian T Meredith; Akiko Maehara; Uday Illindala; Alexandra Lansky; Matthias Götberg; Nicolas M Van Mieghem; Robert Whitbourn; Jean Fajadet; Carlo Di Mario
Journal:  Circulation       Date:  2019-02-05       Impact factor: 29.690

6.  Safety and Performance of Lithoplasty for Treatment of Calcified Peripheral Artery Lesions.

Authors:  Marianne Brodmann; Martin Werner; Todd J Brinton; Uday Illindala; Alexandra Lansky; Michael R Jaff; Andrew Holden
Journal:  J Am Coll Cardiol       Date:  2017-08-15       Impact factor: 24.094

7.  Intravascular Lithotripsy for Treatment of Calcified, Stenotic Iliac Arteries: A Cohort Analysis From the Disrupt PAD III Study.

Authors:  Ehrin J Armstrong; Peter A Soukas; Nicolas Shammas; Jack Chamberlain; Andrei Pop; George Adams; Dorian de Freitas; Javier Valle; Edward Woo; Nelson L Bernardo
Journal:  Cardiovasc Revasc Med       Date:  2020-03-02

8.  Mesenteric artery disease in the elderly.

Authors:  Kimberley J Hansen; David B Wilson; Timothy E Craven; Jeffrey D Pearce; William P English; Matthew S Edwards; Juan Ayerdi; Gregory L Burke
Journal:  J Vasc Surg       Date:  2004-07       Impact factor: 4.268

9.  Intravascular Lithotripsy for Treatment of Calcified Lower Extremity Arterial Stenosis: Initial Analysis of the Disrupt PAD III Study.

Authors:  George Adams; Nicolas Shammas; Sarang Mangalmurti; Nelson L Bernardo; William E Miller; Peter A Soukas; Sahil A Parikh; Ehrin J Armstrong; Gunnar Tepe; Alexandra Lansky; William A Gray
Journal:  J Endovasc Ther       Date:  2020-04-03       Impact factor: 3.487

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.